Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0000905148-25-001076

Options or other derivatives

  • Chief Legal Officer acquired 15,616 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Miller Mary Chief Legal Officer 2025-04-01 Grant or award · Stock Option (Right to Buy) +15,616 15,616 D
Loading xslF345X05/form4.xml…